Early-Phase Clinical Development & Translational Medicine Services
End-to-end early clinical development, from first-in-human and proof-of-concept trials to regulatory submissions, biomarker translation, bioanalysis and clinical supply, delivered by one senior team with a single point of contact.
Moving a drug candidate from the lab into people usually means coordinating several separate vendors: regulatory, clinical operations, bioanalysis, data analysis and drug supply. Each handover adds time and risk. Evotec brings these functions together in one integrated clinical development and translational medicine group. It connects directly to Evotec's preclinical, CMC and biomarker teams, so a program can move from discovery to proof of concept without changing partners.
Evotec supports first-in-human and early-phase studies in healthy volunteers and patients, with particular expertise in oncology. A clinical strategy group helps turn preclinical biomarkers into meaningful human endpoints. Partner clinical sites in Europe and the USA sit close to Evotec's facilities, and sponsors can also use any qualified site of their choice. In real projects, this close integration has cut Phase I timelines by around five to six months.
Evotec’s key capabilities include:
- Clinical strategy, study design and operational management
- First-in-human and early-phase clinical studies
- Translational medicine and biomarker strategy
- PK, PK/PD and population PK modeling
- Clinical data management and biostatistics
- Bioanalytical method development, validation and sample analysis
- Regulatory strategy, CTA/IND preparation and submissions
- Pediatric development planning
- Clinical supply manufacturing, packaging and logistics
- Integration with preclinical, pharmacometrics and other drug development functions
From dose escalation to dose optimization through Model-Informed Drug Development
Friday, October 30 at 15:00 GMT | 16:00 CET | 11:00 EDT | 08:00 PDT
Selecting the right dose can be one of the most critical decisions in clinical development. New approaches are helping teams move beyond traditional toxicity-driven dose escalation, bringing together safety, pharmacokinetic/pharmacodynamic (PK/PD), biomarker, and emerging efficacy data to make more informed decisions earlier in development.
In this SelectScience® webinar, Dr. Cristina Costantin, who brings more than 20 years of experience leading early-stage clinical development programmes across multiple drug modalities, and Andrea Nizzardo, an expert in clinical biometry, PK/PD, pharmacometrics, and model-informed development, will explore how organizations can put Model-Informed Drug Development (MIDD) into practice and use it to drive more confident decision-making during early clinical studies.
With the recent finalization of the International Council for Harmonisation (ICH) M15 guideline, the use of model-informed evidence is becoming an increasingly important part of the clinical development landscape. Drawing on perspectives from both clinical operations and clinical biometry, our expert speakers will discuss how data from safety assessments, PK/PD analyses, biomarkers, and early efficacy endpoints can be brought together to support dose and cohort decisions while studies are still ongoing.
By attending this webinar, you will gain practical insights into planning model-informed strategies from the outset, ensuring critical data are available when key decisions need to be made. Learn how integrating emerging evidence can reduce uncertainty, guide dose optimization, and target population selection, and build a stronger pathway from early clinical development to later-stage success.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
Cost: Free to attend
Location: Online
Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Applying model-informed drug development moves dosing beyond escalation
Evotec experts explain how timely evidence, integrated modeling, and cross-functional collaboration can support better-informed dose optimization decisions
















